Morgan Stanley foresees that
Gilead Sciences (GILD) will prosper due to fading uncertainties in the
biopharma policy by
2026. Multiple
investment firms like Allspring Global Investments Holdings, Miracle Mile Advisors, and CapWealth Advisors increased their positions in GILD. GILD reached a pricing agreement with the US government to reduce drug costs causing the stocks to rise despite a market dip. Post the positive phase 3 data for its
Bictegravir–Lenacapavir HIV regimen, GILD's valuation increased. Daniel Patrick O'Day, however, sold 10,000 shares causing concerns. Mizuho lifted GILD's stock outlook owing to a stronger Biktarvy timeline and Zacks Research raised Q3 EPS forecast for GILD. The company exceeded Q3 expectations as per NASDAQ and is on the verge of a breakout, driving positive market sentiment. GILD continually gains attention from investors and analysts alike with numerous bullish forecasts and upgraded earnings guidance. The stocks soared as multiple firms, including Highland Capital Management, acquired substantial GILD shares. Wells Fargo issued a positive forecast for GILD's stock price. However, Arcus Biosciences broke its winning eight-month streak reportedly due to a decision regarding GILD partnered study.
Gilead Sciences GILD News Analytics from Tue, 15 Jul 2025 07:00:00 GMT to Sat, 03 Jan 2026 14:41:37 GMT -
Rating 6
- Innovation 7
- Information 8
- Rumor -3
